Bimeda Adds Phenylbutazone To Equine Range

Butagran Equi (phenylbutazone) joins Bimeda’s list of analgesic and anti-inflammatories. Available as a sweetened powder, Butagran Equi provides rapid onset of activity with added convenience for horse owners or professionals, according to manufacturer, Bimeda Indications include musculo-skeletal conditions that require relief from pain and a reduction in the associated inflammation, including lameness associated with osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation. Head of Bimeda technical services Padraig Hyland MVB explains: “Butagran Equi is particularly suited where continued mobility is considered desirable. It is also of value in limiting post-surgical inflammation, myositis and other soft tissue inflammation and can be used as an anti-pyretic where this is considered advisable, such as in viral respiratory infections. And being a sweetened powder it’s quite straightforward for horse owners to administer and dose as prescribed,” he notes. The launch is part of Bimeda’s continued investment in the UK market and, according to Mr Hyland, demonstrates the company’s commitment to the UK commercial veterinary sector. “Butagran Equi follows the launch of a number of new products and is proof our desire to provide a comprehensive and relevant equine portfolio backed up with first class technical support,” he concludes.

More from

• Vetsure Named Business of the Year at 2025 SME National Business Awards
• Home of hope for Romania's dogs: The pioneering shelter doing things differently
• Pioneering new locum platform transforming veterinary landscape
• Key Stakeholders unite to advance helmet design for equine veterinary professionals
• Hallmarq hails transformational equine imaging technology